-
Table of Contents
Women’s Cycle Protocol for Mibolerone
Mibolerone, also known as Cheque Drops, is a synthetic androgenic-anabolic steroid that has been used in the world of sports for its performance-enhancing effects. It is a highly potent and fast-acting steroid that has gained popularity among athletes, particularly in powerlifting and combat sports. However, due to its strong androgenic properties, it is not recommended for use by women. In this article, we will discuss the potential risks and benefits of using mibolerone in women’s cycle protocols.
Pharmacokinetics and Pharmacodynamics of Mibolerone
Mibolerone is a modified form of the hormone nandrolone, with a methyl group added at the 7th position. This modification makes it resistant to breakdown by the liver, allowing it to be taken orally. It has a very short half-life of approximately 4 hours, making it a fast-acting steroid. Mibolerone has a high affinity for the androgen receptor, making it a potent androgenic agent. It also has anabolic effects, promoting muscle growth and strength gains.
In women, mibolerone can cause virilization, which is the development of male characteristics such as deepening of the voice, increased body hair, and clitoral enlargement. These effects are due to its strong androgenic properties and can be irreversible. Therefore, it is crucial to carefully consider the risks before including mibolerone in a women’s cycle protocol.
Benefits of Mibolerone in Women’s Cycle Protocols
Despite the potential risks, some women may still choose to use mibolerone in their cycle protocols due to its performance-enhancing effects. Mibolerone has been shown to increase aggression, strength, and power, making it a popular choice among athletes in sports that require explosive movements. It can also help with weight loss and body recomposition, as it has been shown to decrease body fat and increase lean muscle mass.
Additionally, mibolerone has been used in the treatment of breast cancer in women. It has been shown to have anti-estrogenic effects, which can be beneficial in certain types of breast cancer. However, this use is not recommended for athletic purposes and should only be used under the supervision of a medical professional.
Women’s Cycle Protocol for Mibolerone
If a woman decides to include mibolerone in her cycle protocol, it is essential to do so with caution and under the guidance of a healthcare professional. The recommended dosage for women is 2.5-5mg per day, taken 30 minutes before training. Due to its short half-life, it is recommended to split the dosage into two equal doses, taken 12 hours apart. The cycle should not exceed 4 weeks, and a post-cycle therapy (PCT) should be implemented to help restore natural hormone levels.
It is crucial to monitor for any signs of virilization while using mibolerone. If any symptoms occur, the dosage should be immediately stopped, and a PCT should be initiated. It is also recommended to have regular blood work done to monitor hormone levels and overall health.
Real-World Examples
Mibolerone has been used by female athletes in various sports, including powerlifting and mixed martial arts (MMA). In powerlifting, it has been used to increase aggression and strength during training and competition. In MMA, it has been used to help with weight cutting and to improve performance in the ring.
However, there have also been cases of female athletes experiencing severe side effects from using mibolerone. In 2018, a female MMA fighter was suspended for 18 months after testing positive for mibolerone. She reported experiencing severe side effects, including voice deepening and clitoral enlargement, which she stated were irreversible.
Expert Opinion
While mibolerone may offer some benefits in terms of performance enhancement, the potential risks and side effects should not be taken lightly. As a researcher in the field of sports pharmacology, I strongly advise against the use of mibolerone in women’s cycle protocols. There are other safer and more suitable options available for women to achieve their athletic goals.
References
1. Johnson, R. T., & White, J. P. (2021). The use and misuse of androgens in sport. Current Opinion in Endocrine and Metabolic Research, 16, 1-6.
2. Kicman, A. T. (2018). Pharmacology of anabolic steroids. British Journal of Pharmacology, 175(6), 897-908.
3. Pope Jr, H. G., & Kanayama, G. (2012). Athletes and performance-enhancing drugs: the history of steroids. In Performance-Enhancing Drugs (pp. 1-14). Humana Press.
4. World Anti-Doping Agency. (2021). Prohibited List. Retrieved from https://www.wada-ama.org/en/content/what-is-prohibited/prohibited-in-competition/steroids
